Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Dean Slagel currently holds 1,064,338 shares of Cara Therapeutics, Inc. (CARA), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Dean Slagel has been a net seller of CARA stock. They have purchased $0 and sold $9.9M worth of shares.
Dean Slagel's most recent insider trade was on Jun 29, 2017, when they sold 20,862 shares at $26.58 per share.
Dean Slagel serves as Executive at Cara Therapeutics, Inc. (CARA). They have executed 11 insider transactions totaling $9.9M over their tenure at the company.
Dean Slagel holds the position of Executive at Cara Therapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 12 years and currently hold a stake valued at $0.
Dean Slagel has shown a selling trading pattern, with $0 in total purchases and $9.9M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Dean Slagel was on Jun 29, 2017, when they sold $5.9M worth of CARA shares. This transaction involved 229,138 shares at $25.81 per share.
Dean Slagel currently owns 1,064,338 shares of Cara Therapeutics, Inc. (CARA), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Dean Slagel's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Dean Slagel has 11 Form 4 filings on record as an insider at Cara Therapeutics, Inc..
Set alerts for Dean Slagel and 40,000+ other insiders.